.avif)
Passage BIO Email Format
Biotechnology Research
・
51-200 employees
・
Philadelphia, PA, USA
Passage BIO is a clinical-stage genetic medicines company developing one-time therapies to treat neurodegenerative diseases by targeting underlying disease pathology.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
firstinitiallast@passagebio.com
Company Overview
Industry
Biotechnology Research
Founded
2017
Headquarters
Philadelphia, PA, USA
Revenue
$25M-$50M
FUNDING Stage
Public
Website
Key Executives
William Chou (President and Chief Executive Officer), Kathleen Borthwick (Chief Financial Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Passage BIO?
Passage BIO uses the firstinitiallast format, so Jane Smith would be jsmith@passagebio.com.
What is Passage BIO's lead clinical program and which disease does it target?
Passage BIO's lead program is PBFT02, an AAV1-based gene therapy administered via a single intracisterna magna injection that targets frontotemporal dementia caused by GRN or C9orf72 mutations, and it is currently being evaluated in the Phase 1/2 upliFT-D clinical trial.
Who leads Passage BIO as its chief executive officer?
William Chou serves as President and Chief Executive Officer of Passage BIO, with Kathleen Borthwick serving as Chief Financial Officer. You can use Clay to quickly verify current leadership contacts and find verified email addresses for the Passage BIO team.
How many employees does Passage BIO have at its Philadelphia headquarters?
Passage BIO is based in Philadelphia, PA and has approximately 52 employees. Clay can help you identify and enrich specific contacts at Passage BIO if you are building a targeted outreach list.
Beyond frontotemporal dementia, what other neurodegenerative conditions is Passage BIO researching?
In addition to frontotemporal dementia, Passage BIO is pursuing gene therapy programs targeting amyotrophic lateral sclerosis, Alzheimer's disease, and Huntington's disease, all centered on CNS-directed AAV delivery approaches.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating